When: zola-cel pause scope resolved (re-initiation or confirmed autoimmune-only containment)

Then: Re-evaluate for potential re-engagement; if single trigger fires alone, reassess sizing

When: Two or more triggers fire concurrently

Then: Consider adding 25% of intended incremental size

When: Price breaks above $68.64-69.18 on >13M shares with MACD re-acceleration

Then: Re-engage add trigger above breakout level

REDUCE - Trim 25 to 40 percent of BMY exposure in tranches above 65.50 over a one to two week window; do not pre-commit to reload at 58; hold residual position for income; no new entries until technicals confirm.

• Forward P/E of 9.86 times with PEG of 2.5 prices in skepticism about consensus EPS; 3.77 percent yield does not indicate a value setup.
• MACD crossed below signal, RSI cooled from 70 to 46, price slipped below 10-EMA, Bollinger middle band, and VWAP simultaneously—momentum has broken.
• Zola-cel WSJ coverage framed as 'drugmakers halt trials after deaths' is class-level overhang; retail message board silence confirms thin, income-driven bid.
• Hold is not a free option; if Eliquis erosion starts late 2026 and multiple compresses from 9.86 to 8 times, that is a 20 percent drawdown before earnings revisions.
• Dividend cushions income but not principal; low beta of 0.227 does not protect from fundamental derating.
• Aggressive analyst's trim requires stock to rally from 64.69 into 67.50 to 68.50 zone despite just-broken momentum—this contradicts the bearish signal.
• Reload stop at 57.40 sits exactly at 200-day MA; stop-loss hunting around round-number secular support is a documented phenomenon, especially with 45 billion dollars of goodwill and known catalyst window.
• Foregone dividends during wait equal roughly 4 percent of position value (0.63 per quarter, 2.52 annualized); reload math must clear this hurdle.
• Residual position at 3.77 percent yield with 1.6 times free cash flow coverage and intact 200-day MA is a legitimate defensive allocation.
• Conservative approach is to reduce exposure before catalyst, not after; discipline is reducing when risk-reward deteriorates, not defending full position.

→ vs aggressive: Trim plan assumes stock rallies from 64.69 into 67.50 to 68.50 zone despite MACD freshly bearish and price below every short-term momentum reference—selling into a falling knife is hoping, not disciplined risk management.

→ vs aggressive: Reload stop at 57.40 sits exactly on the 200-day MA; stops on secular support levels get hunted, and the plan will be stopped out before any bounce materializes.

→ vs aggressive: Trim-and-reload math ignores dividend cost of roughly 4 percent of position value foregone during wait; the trade is net negative even if executed perfectly unless reload clears this hurdle.

→ vs neutral: Hold is an active bet that the long-term trend survives a known catalyst window; low beta of 0.227 does not protect from fundamental derating—it just means you get there slowly.

→ vs neutral: Dividend cushions income, not principal; if Eliquis erosion starts late 2026 and multiple compresses to 8 times from 9.86 forward, that is a 20 percent drawdown on top of earnings revisions.

SELL; trim 35-40% over 2-3 weeks at current levels using TWAP/VWAP; define reload review triggers rather than pre-commit entry; redeploy freed capital with portfolio context

• Trim 35-40% of position (upper end of trader's 25-40% range) rather than waiting for rally to 67.50-68.50 or sustained move above 65.50
• Execute trim at current levels using TWAP or VWAP approach sized to ATR of 1.58 to minimize market impact
• Do not pre-commit reload entry at 58 (9% risk, telegraphed level); do not passively 'let residual ride'
• Three reload review triggers: (1) Technical repair—MACD histogram positive, RSI reclaims 50, price reclaims 10-EMA at 66.59; (2) Structural—confirmed test and hold of 200-day MA at 57.40 with bullish divergence; (3) Fundamental—clarity on zola-cel pause scope (re-initiation or autoimmune program contained)
• Redeploy freed capital with portfolio context; higher-for-longer macro and geopolitical tail risk may offer better risk-adjusted uses than cash waiting for BMY at 58
• Keep residual core position for income (3.77% yield) and defensive characteristics; oncology CAR-T franchise (Breyanzi, Abecma) is unaffected by zola-cel autoimmune pause
• Current technical setup: price 64.69, MACD freshly bearish, RSI 46 cooling from 70, below 10-EMA (66.59), below VWMA, below Bollinger middle band, 22% above 200-day MA (57.40)
• Key support levels: 50-SMA at 63, Bollinger lower band at 63.20
• Aggressive trim zone 67.50-68.50 and conservative trigger above 65.50 both represent waiting for levels market has shown no intention of returning to
• Q2 2026 EBITDA up 56% YoY; 5.9 billion debt reduction over four quarters; FCF coverage of dividend at 1.6x; ROE 46.6%; beta 0.227
• Forward P/E 9.86x with 2.5 PEG suggests market has already priced in some Eliquis skepticism; Q2 2026 EPS 1.62 running close to 6.56 annual estimate

→ vs aggressive: Trim assumes rally to 67.50-68.50 will materialize but momentum has rolled and price is below every short-term reference; conditioning entire trade on level market has shown no intention of returning to is cart before horse

→ vs aggressive: Reload at 58 is a textbook level that gets run; 60-cent stop on 6.50 entry equals ~9% risk on reload leg, which is telegraphed risk management; doesn't account for chop scenario where stock moves sideways 60-65 for 3 months

→ vs aggressive: Treating BMY as tactical trade instead of income allocation with defensive equity wrapper; only models bear case, misses potential multiple expansion as tailwind if company continues to deliver

→ vs conservative: 30% trim still leaves 60-75% of position exposed to worst-case (20% multiple compression plus EPS revision); prescription doesn't follow from own accurate diagnosis

→ vs conservative: 'Sustained move above 65.50' is same conditional execution as aggressive analyst's rally; needs the same hope just at lower price given broken momentum

→ vs conservative: 'Let residual ride with dividend' ignores deteriorating technical setup (bearish MACD, RSI cooling from 70, below 10-EMA and VWMA on above-average volume, 22% above 200-day); beta 0.227 doesn't protect from fundamental derating, just means slower arrival

→ vs conservative: Doesn't engage with distinction between zola-cel autoimmune pause and oncology CAR-T franchise (Breyanzi, Abecma); bear case should price this distinction but doesn't